Key facts
- This page summarizes Kyle Rasbach's Form 3 filing for Lexeo Therapeutics, Inc. (LXEO).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Dec 2024, 14:59.
Kyle Rasbach - 18 Dec 2024 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- LXEO
- Reported as of
- 18 Dec 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 27 Dec 2024, 14:59:55 UTC
- Next SEC filing
- 22 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Youjin Choi, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kyle Rasbach filed Form 3 for Lexeo Therapeutics, Inc. (LXEO) on 27 Dec 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.